Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$5.26 USD
-0.13 (-2.41%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.25 -0.01 (-0.19%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 1 - 20 ( 125 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
sNDA Submitted For Full Approval of FILSPARI For IgAN; Approval in Europe Expected in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: Sparsentan Receives Positive CHMP Opinion; sNDA Submission for Full U.S. Approval in 1Q24; Trim PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Flipping Forward: 4Q23 Report As Anticipated, While Filspari Launch Progresses
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NNARR Below Buyside Expects; ARR Guided Down; Is FY25E Guide at Risk?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Travere Signs Agreement For Sparsentan in Asia; IgAN Registrational Study in Japan to Begin in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary 4Q FILSPARI Sales Exceed Our Estimates; Kicking Off 2024 With Two Regulatory Decisions in 1Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Drug Prices for the New Year; We Highlight Three Recent Price Changes in Our Coverage Universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Filspari Continues To Make Progress As TVTX Preannounces Beat
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 HARMONY Study of Pegtibatinase to Support First Potential Disease-Modifying Therapy For HCU; PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
sNDA Filing Planned in 1Q24 For FILSPARI''s Full Approval in IgAN; Reorganization Extends Cash Runway to 2028; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IgAN sNDA Advances, FSGS No Go While Workforce Reduction Hits
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for TVTX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Filspari Fizzled A Bit in 3Q23, But Continue To Receive Positive Doc Feedback
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The IgAN Era Continues, While Xphozah Makes A Splash Ahead Of Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Commercial Preview: Some Fireworks Ahead, But Prereleases Steal Thunder
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kidney Week 2023 - Gearing Up For What''s New in Glomerular Disease
Provider: Wedbush Securities Inc.
Analyst: CHICO L